



3 August 2023

ASX Announcement

Change of Company Secretary and Registered Office Address

InhaleRx Limited ("Company") in accordance with ASX Listing Rule 3.16.1, is pleased to announce the appointment of James Barrie as Company Secretary effective from today's date. Mr Barrie is a professional Company Secretary and Director, and the Board welcomes his input moving forward.

Elizabeth Spooner and Nova Taylor of Automic Group will step down as Joint Company Secretaries effective 3 August 2023. The Board would like to acknowledge the contribution of Elizabeth Spooner and Nova Taylor during their tenure.

For the purpose of ASX Listing Rule 12.6, James Barrie will be the person responsible for communications between the Company and ASX.

The Company also advises that the Registered Office address of the Company has changed to:

C/- Prime Company Compliance, Level 16, 414 La Trobe Street, Melbourne VIC 3000

This announcement has been approved for release to ASX by the InhaleRx board of directors.

For further information:

www.inhalerx.com.au

James Barrie
Company Secretary

About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au

InhaleRx Limited (ASX: IRX) ("InhaleRx" or "the Company") is an Australian healthcare company which is developing unique medicinal drug-device products to address unmet medical needs in pain management and mental health sectors.

The overarching goal is to pursue U.S. FDA approval and registration to treat Panic Disorder and pain using rapid and cost effective regulatory pathways, such as 505(b)(2). A 505(b)(2) application is an New Drug Approval (NDA) that contains full reports of investigations of safety and effectiveness, where at least some of the information required for approval comes from studies available in the public domain.

There is a significant economic opportunity for InhaleRx and the Company's shareholders as these carefully selected medical indications under investigation currently have extremely limited treatment options, whilst also offering a low side effect profile.

InhaleRx holds an innovation patent and provisional patents for the nominated indications and the company plans to continue to strengthen this position.